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Abstract
Background: This study aimed to identify patient-reported outcomes and clinician-assessed characteristics of the
first metatarsophalangeal joint (1MTPJ) in people with gout and with asymptomatic hyperuricaemia by comparing
them to normouricaemic controls.
Methods: Twenty four people with gout (without current symptoms of acute arthritis), 29 with asymptomatic
hyperuricaemia and 34 age- and sex-matched controls participated in this cross-sectional observational study.
Patient-reported outcomes included 1MTPJ pain, foot pain and disability, body pain, lower limb function, activity
limitation and overall wellbeing. Clinician-assessed characteristics of the 1MTPJ included range of motion (ROM),
plantar- and dorsi-flexion force, foot posture, temperature and hallux valgus severity.
Results: Compared to controls, participants with gout reported greater 1MTPJ pain (p = 0.014), greater foot pain and
disability (p < 0.001), increased odds of having disabling foot pain (odds ratio (OR) 13.4, p < 0.001), decreased lower
limb function for daily living (p = 0.002) and recreational (p < 0.001) activities, increased activity limitation (p = 0.002),
reduced overall wellbeing (p = 0.034), reduced ROM (p < 0.001), reduced plantarflexion force (p = 0.012), increased
1MTPJ plantar (p = 0.004), dorsal (p = 0.003) and medial (p = 0.004) temperature and had increased odds of having
more severe hallux valgus (OR 0.3 p = 0.041). Compared to controls, participants with asymptomatic hyperuricaemia
had increased odds of having disabling foot pain (OR 4.2, p = 0.013), increased activity limitation (p = 0.033), decreased
lower limb function for daily living (p = 0.026) and recreational (p = 0.010) activities, increased 1MTPJ plantarflexion
force (p = 0.004) and a more pronated foot type (p = 0.036).
Conclusions: People with gout demonstrate 1MTPJ-specific changes indicative of subclinical inflammation, even in the
absence of acute arthritis. People with asymptomatic hyperuricaemia, who exhibit no features or symptoms of gout,
also report high levels of foot- and lower limb-related pain and disability.
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Background
Gout is the most common form of inflammatory arth-
ritis in middle-aged men [1, 2]. Abnormally high levels
of urate in the blood, termed hyperuricaemia (defined as
≥0.41 mmol/L), is the most important risk factor in the
development of gout [3]. The prevalence of gout and
hyperuricaemia is increasing worldwide [4–7]. Hyperur-
icaemia can lead to the formation and deposition of
monosodium urate (MSU) crystals in joints and soft
tissues, and consequent clinical manifestations of gout,
including episodes of acute gouty arthritis and tophus
formation [8, 9]. Not all individuals with hyperuricae-
mia develop clinical features of gout [10–12]. However,
recent imaging studies have reported the presence of
MSU crystal deposition and subclinical joint- and
extra-articular-damage in people with asymptomatic
hyperuricaemia [13–19]. The clinical significance of
these findings is currently unclear [20].
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Acute gouty arthritis most commonly affects the first
metatarsophalangeal joint (1MTPJ) [11, 21–23]. Ad-
vanced imaging studies have shown MSU crystal depos-
ition frequently occurs within this joint not only in
people with gout [24–26], but also in people with
asymptomatic hyperuricaemia [14, 16]. People with
gout report significant foot pain and report impairments
and disability with everyday activities, including walking
[27, 28]. In fact, they exhibit plantar pressure patterns and
gait strategies consistent with an attempt to offload pain
at the 1MTPJ [29]. Despite the importance of 1MTPJ
function, particularly during the propulsive phase of gait
[30, 31], the effect of gout and asymptomatic hyperuricae-
mia on patient-reported outcomes and clinical character-
istics of the joint is unclear. This study therefore aims to
identify patient-reported and clinician-assessed character-
istics of the 1MTPJ in people with gout and people with
asymptomatic hyperuricaemia by comparing them to nor-
mouricaemic controls.
Methods
Participants
This investigation was a cross-sectional observational
study. Gout participants were recruited from Auckland
District Health Board, Auckland, New Zealand. All
participants fulfilled the 1977 preliminary American
Rheumatism Association classification criteria for gout
[21]. Participants without gout were recruited from
Auckland University of Technology (AUT) staff. Non-
gout participants underwent serum urate capillary test-
ing on the day of the study using a Reflotron® Plus
(Roche Diagnostics Ltd., New Zealand) and were strati-
fied into either the asymptomatic hyperuricaemic group
(serum urate ≥0.41 mmol/L) or the normouricaemic
control group (serum urate <0.41 mmol/L). The three
groups were age-and sex-matched. Participants were
excluded if they were under 20 years of age; had a his-
tory of other inflammatory arthritis; were experiencing
acute arthritis at the time of the clinical visit; had foot
and/or ankle surgery in the previous 3 months; had a
history of 1MTPJ surgery; lower limb amputation; or
were unable to walk 10 m unaided. Ethical approval for
the study was obtained from the AUT Ethics Committee
(13/100) and locality assessment was obtained from
Auckland District Health Board (A + 5891). All partici-
pants provided written informed consent prior to data
collection.
All data were collected by a single researcher and regis-
tered podiatrist (SS). Demographic data were obtained
from all participants including age, gender, ethnicity, body
mass index (BMI), current medications and medical his-
tory. Additionally, gout disease characteristics were docu-
mented for gout participants including disease duration,
flare history, and tophus presence.
Patient-reported outcomes
Both right and left 1MTPJ pain, general body pain and
patient global over the past week were assessed using
100 mm Visual Analogue Scales (VAS). Foot pain and
disability was assessed using the 19-item Manchester
Foot Pain and Disability Index (MFPDI) [32]. Each item
was answered ‘none of the time’ (scored as 0), ‘on some
days’ (scored as 1) or ‘on most/every day(s)’ (scored as
2) in the past month and a total score out of 38 was
summated for each participant. Additionally, it was
noted whether each participant had the presence of
disabling foot pain, defined as at least one item scored
as 1 or 2 [32]. The Health Assessment Questionnaire -
Disability Index (HAQ-DI) [33] was used to measure
activity limitation in which participants were asked to
rate their ability to perform 10 tasks in the past week
(without difficulty = 0, some difficulty = 1, much diffi-
culty = 2, or unable = 3). The scores were summated and
divided by 10 to give an overall value between 0 (min-
imal loss of function) and 3 (completely disabled). The
Lower Limb Task Questionnaire (LLTQ) [34] was used
to measure lower limb function related to two sections:
activities of daily living (LLTQ daily) and recreational
activities (LLTQ recreational). For each section partici-
pants were asked to rate their difficulty with 10 activities
in the past 24 h (unable = 0, severe difficulty = 1, moder-
ate difficulty = 2, mild difficulty = 3, and no difficulty = 4)
from which a total score out of 40 was calculated.
Clinician-assessed outcomes
Passive, non-weight-bearing 1MTPJ dorsiflexion range of
motion (ROM) was measured using a hand-held goni-
ometer (Whitehall Manufacturing Ltd., California, USA)
in accordance with the procedure outlined by Hopson
and McPoil [35]. Participants were positioned seated
with knees extended and the ankle in neutral. Lines were
drawn on the medial aspect of the foot along the sagittal
bisections of the first metatarsal and proximal phalanx.
The examiner applied a dorsiflexion force to the hallux
until it could no longer be passively moved into further
extension. The angle between the two bisection lines
was measured from the goniometer. Three repeated
measurements of right and left feet were taken.
Isometric muscle force for plantarflexion and dorsiflex-
ion of the 1MTPJ was measured using a CITEC hand-
held dynamometer (CIT Technics, Haren, Netherlands).
Participants were positioned seated with knees extended
and the foot stabilised in a custom-made device com-
prised of two wooden boards angled at 90°. The plantar
foot was positioned against the vertical board with the
ankle in a neutral position. Velcro straps were applied
across the dorsum of the foot and lower leg, to isolate the
1MTPJ and to ensure the lower leg was held stationary.
Strength was assessed using the ‘make’ technique in which
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the examiner held the dynamometer stationary while the
participant exerted maximal force against it [36]. The
dynamometer was positioned against the plantar aspect of
the interphalangeal joint during plantarflexion testing and
on the dorsal aspect of the hallux during dorsiflexion [37].
Three consecutive contractions of three to five seconds
were recorded for each muscle group for each foot.
Hallux valgus severity was assessed using the Manches-
ter Scale [38] which is comprised of four photographs
graded as 0 being ‘no deformity’, 1 being ‘mild deformity’,
2 being ‘moderate deformity’ and 3 being ‘severe defor-
mity’. The participant was asked to stand in a relaxed
weight-bearing position while the examiner used the pho-
tographs to grade the deformity on each foot.
Foot type was assessed using the 6-item Foot Posture
Index (FPI-6) [39] with the participant standing in a re-
laxed weight-bearing position. Each FPI criterion was
scored on a five-point scale (−2 to +2) and a total score
calculated for each foot ranging from −12 (highly supi-
nated) to +12 (highly pronated).
Temperature of the 1MTPJ was measured using a
DermaTemp 1001 (Exergen Corporation, Massachu-
setts), which is a hand-held infrared thermographic
scanner with an in-built sensor. Participants were given
adequate equilibration time in the room (thermostatic-
ally controlled at 22 °C ±2 °C). Temperatures were re-
corded from medial, dorsal and plantar sites of the
1MTPJ. Three readings for each site were repeated for
each foot.
Where repeated measurements were taken, they were
not averaged, but instead included as separate observa-
tions in the analysis as described below.
Data analysis
Demographic and medical data were described as mean
(SD) for continuous data and frequency (%) for categorical
data. All continuous outcomes were reviewed for normal-
ity using the residuals from a linear model, which included
relevant demographic covariates and the participant group
as the independent variables. Appropriate regression
models were identified for each outcome measure. Linear
regression models were used for all continuous outcome
measures. For the presence of disabling foot pain (a di-
chotomous outcome measure) logistic regression was
used. For hallux valgus severity, an ordinal outcome meas-
ure, multinomial regression with cumulative logit link was
used. Where appropriate, models accounted for repeated
measures taken from right and left feet of each participant
through using a mixed models approach in which a
participant-specific random effect and participant-nested
random effects for foot-side were added to the model.
This analysis produces results identical to an analysis of
measures averaged for each foot-side that would allow for
a between-foot-side correlation, and also allows for any
reweighting required due to missing values. For 1MTPJ
temperature, which was measured at three sites (forming
a natural vector of related variables) in addition to the
participant and foot-side random effects, a heterogeneous
compound symmetry covariance structure was employed,
which allowed for separate variances for each site, as well
as different covariances (but equal correlations) between
each pair of sites.
Adjustments for gender, age group and ethnicity, which
were entered into each model simultaneously, were con-
sidered only if their level of observed significance
achieved at least 10 % on an F-test (or equivalent devi-
ance test (i.e. Wald test) for categorical variables). Poten-
tial covariates were also explored by reviewing box plots
of random effects by covariate group. A single-adjusted
model was sought for each category of clinically-assessed
outcome measures (i.e. patient-reported outcomes, struc-
tural and functional outcomes and neurovascular out-
comes). Two contrasts were considered: gout vs. control
and asymptomatic hyperuricaemia vs. control, which
were always tested separately. All hypothesis tests (ex-
cluding covariate testing) were carried out at a 5 % level
of significance against two-sided alternatives. No adjust-
ment for multiplicity was used, but all test-statistics, their
null distributions and their observed significance levels
were reported. Data were analysed using IBM SPSS
Statistics version 20 and SAS version 9.3.
Results
A total of 87 participants were included with 24 in the
gout group, 29 in the asymptomatic hyperuricaemic
group and 34 controls. Demographic and clinical charac-
teristics for the three groups are shown in Table 1. All
participants were male with a mean (SD) age of 58 (15)
years and predominantly of European ethnicity (n = 68,
81 %). The control group had a significantly lower mean
BMI compared to the gout (p < 0.001) and asymptomatic
hyperuricaemic participants (p < 0.001). Compared to
controls, participants with gout had a significantly
higher frequency of NSAID use (p = 0.004). The control
group had a significantly lower prevalence of hyperten-
sion compared to the gout (p = 0.001) and asymptomatic
hyperuricaemic groups (p = 0.023) and a significantly
lower prevalence of cardiovascular disease compared to
the gout group (p = 0.019). People with gout also had
significantly higher mean tender (p = 0.032) and swollen
joints counts (p < 0.001) compared to controls.
Disease characteristics for the gout group are shown
in Table 2. Gout participants were found to have a long
disease duration with a mean (SD) of 17 (11) years, with
71 % (n = 17) having tophaceous gout and 96 % (n = 23)
on urate lowering therapy. The majority of participants
with gout reported a history of acute 1MTP arthritis on
either foot (n = 21, 88 %).
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The distribution of residuals from the linear models for
all outcome measures demonstrated sufficient normality
to carry out parametric testing. All final models were
adjusted for age group. Table 3 displays the mean esti-
mates and inferential statistics for all patient-reported
outcomes. Compared to controls, participants with gout
reported significantly greater 1MTPJ pain (p = 0.014),
greater patient global scores (p = 0.034), a greater HAQ-
DI score (p = 0.002), a greater LLTQ daily score (p =
0.002), a greater LLTQ recreational score (p < 0.001), a
greater MFPDI score (p < 0.001), and a higher odds of
having disabling foot pain (OR 13.4; p < 0.001). Partici-
pants with asymptomatic hyperuricaemia also reported a
significantly greater HAQ-DI score (p = 0.033), a greater
LLTQ daily score (p = 0.026), a greater LLTQ recreational
score (p = 0.010) and had a higher odds of having disab-
ling foot pain (OR 4.2 p = 0.013), compared to controls.
Table 4 displays the mean estimates and inferential sta-
tistics for all clinician-assessed outcomes. Compared to
controls, participants with gout had significantly reduced
1MTPJ ROM (p < 0.001), reduced 1MTPJ plantarflexion
force (p = 0.012), an increased odds of having more
severe hallux valgus (OR 0.3; p = 0.041) and increased
temperature at the plantar (p = 0.004), dorsal (p = 0.003),
Table 1 Demographic and medical characteristics
Variable Gout Asymptomatic hyperuricaemia Control
N 24 29 34
Gender, male, n (%) 24 (100 %) 29 (100 %) 34 (100 %)
Age, years, mean (SD) 58 (13) 58 (19) 58 (14)
Ethnicity, n (%) European 14 (58 %) European 24 (83 %) European 30 (88 %)
Maori 1 (4 %) Maori 0 (0 %) Maori 1 (3 %)
Pacific 5 (21 %) Pacific 3 (10 %) Pacific 0 (0 %)
Asian 4 (17 %) Asian 2 (7 %) Asian 3 (9 %)
BMI, kg/m2, mean (SD) 30.2 (4.0)* 29.3 (5.9)* 25.0 (2.9)
Diuretic use, n (%) 3 (12 %) 7 (24 %) 4 (12 %)
NSAID use, n (%) 14 (58 %)* 11 (38 %) 7 (21 %)
Prednisone use, n (%) 5 (21 %) 0 (0 %) 0 (0 %)
Hypertension, n (%) 17 (70 %)* 16 (55 %)* 9 (26 %)
Cardiovascular disease, n (%) 7 (29 %)* 5 (17 %) 1 (3 %)
Diabetes, n (%) 4 (17 %) 1 (3 %) 2 (6 %)
Urate, mmol/l Mean (SD) 0.35 (0.10) 0.46 (0.05)* 0.32 (0.06)
Range 0.24 - 0.63 0.41 - 0.63 0.20 - 0.40
1MTPJ tenderness, n (%) Right 4 (17 %) 1 (0 %) 0 (0 %)
Left 3 (12 %) 0 (0 %) 1 (3 %)
1MTPJ swelling, n (%) Right 1 (4 %) 0 (0 %) 0 (0 %)
Left 0 (0 %) 0 (0 %) 0 (0 %)
66/68 joint count, mean (SD) Tender 2.7 (6.1)* 1.5 (1.9) 0.6 (1.2)
Swollen 1.0 (1.7)* 0.2 (0.7) 0.0 (0.0)
*Significantly different from controls (p < 0.05)
Table 2 Gout disease characteristics
Variable Gout
Classification criteria Aspirate proven 6 (25 %)
Clinical criteria 18 (75 %)
Disease duration, years, mean (SD) 17 (11)
Age of onset, years, mean (SD) 41 (18)
Acute flares in preceding 3 months, mean (SD) 1.3 (1.4)
1MTPJ flares in preceding 3 months, n (%) 6 (25 %)
History of 1MTPJ flares, n (%) 21 (88 %)
Presence of subcutaneous tophi, n (%) 17 (71 %)
Presence of 1MTPJ tophi, n (%) 6 (25 %)
Number of tophi in feet, mean (SD) 1.9 (3.5)
Total number of tophi, mean (SD) 6.1 (8.7)
Colchicine use, n (%) 13 (54 %)
Urate lowering therapya, n (%) 23 (96 %)
Allopurinol use, n (%) 19 (79 %)
Probenecid use, n (%) 3 (12 %)
Benzbromarone use, n (%) 2 (8 %)
Febuxostat use, n (%) 2 (8 %)
a3 patients were taking >1 urate lowering agent
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and medial (p = 0.004) aspects of the 1MTPJ. Partici-
pants with asymptomatic hyperuricaemia had signifi-
cantly greater 1MTPJ plantarflexion force (p = 0.004)
and a higher FPI score (p = 0.036), compared to controls.
Discussion
This study investigated patient-reported outcomes and
clinician-assessed characteristics of the 1MTPJ in people
with gout and people with asymptomatic hyperuricae-
mia. Despite the absence of current symptoms of acute
arthritis in the gout participants and an absence of any
signs or symptoms of gout in the asymptomatic hyperur-
icaemic participants, both groups reported high levels of
foot- and lower limb-related pain and disability. Add-
itionally, people with gout demonstrated 1MTPJ-specific
changes related to pain, joint motion, muscle strength,
hallux valgus severity and temperature.
Clinical symptoms in gout are generally associated
with acute episodes of painful inflammatory arthritis,
most often at the 1MTPJ [21], while intercritical periods
are considered to be ‘asymptomatic’ remissive phases
[40, 41]. However, our findings, which support existing
research [42, 43], suggest that 1MTPJ pain may be a
chronic and persistent foot problem in people with gout.
These results may be explained by the presence of sub-
clinical inflammation, which is further emphasised by
the increased 1MTPJ temperature observed in the gout
participants in this study [44]. It has been well estab-
lished that MSU crystals, which promote the inflamma-
tory response evident in acute gout, are also present in
synovial fluid during intercritical periods [45]. Further-
more, imaging studies have frequently observed synovitis
in gout patients in the absence of clinically evident in-
flammation [25, 46, 47]. The clinical relevance of persist-
ent inflammation at the 1MTPJ in people with gout is
uncertain.
This study has also identified a number of structural
and functional changes at the 1MTPJ in people with
Table 3 Patient-reported outcomes
Parameter Mean
estimate
Diff. 95 % CI p
Lower Upper
1MTP pain VAS (mm) Control (ref.) 1.7
Gout 8.4 6.7 1.4 12.0 0.014
Asymptomatic hyperuricaemia 6.6 4.9 −0.1 10.0 0.055
General pain VAS (mm) Control (ref.) 18.0
Gout 21.8 3.8 −9.9 17.5 0.581
Asymptomatic hyperuricaemia 29.2 11.3 −1.7 24.3 0.088
Patient global VAS (mm) Control (ref.) 11.5
Gout 23.6 12.0 0.9 23.1 0.034
Asymptomatic hyperuricaemia 21.3 9.8 −0.8 20.3 0.068
HAQ-DI Control (ref.) 0.11
Gout 0.44 0.33 0.13 0.54 0.002
Asymptomatic hyperuricaemia 0.32 0.21 0.02 0.41 0.033
LLTQ - daily Control (ref.) 38.6
Gout 33.3 −5.3 −8.6 −2.0 0.002
Asymptomatic hyperuricaemia 35.0 −3.6 −6.8 −0.4 0.026
LLTQ – recreational Control (ref.) 34.2
Gout 20.8 −13.4 −19.0 −7.9 <0.001
Asymptomatic hyperuricaemia 27.2 −7.0 −12.3 −1.8 0.010
MFPDI Control (ref.) 1.826
Gout 13.3 11.5 7.7 15.3 <0.001
Asymptomatic hyperuricaemia 3.0 1.2 −2.4 4.8 0.511
Odds ratio 95 % CI for OR p
Lower Upper
Presence of disabling foot pain Control (ref.)
Gout 13.4 3.69 48.68 <0.001
Asymptomatic hyperuricaemia 4.2 1.36 12.8 0.013
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gout. Although restricted 1MTPJ motion may be a
result of surrounding synovial inflammation or a pain-
avoidance mechanism, previous research has regarded
reduced 1MTPJ motion in people with gout as a
clinical measure of osteoarthritis [43]. It has been
suggested that osteoarthritis may predispose to local-
ised MSU crystal deposition and thus may explain the
tendency for gout to affect the 1MTPJ [43, 44]. How-
ever, it remains uncertain whether osteoarthritis
precedes gout or whether joint damage results from
chronic gouty arthritis and/or mechanical obstruction
by tophi [45].
Participants with gout also exhibited a reduction in
1MTPJ plantarflexion force. Considering the import-
ance of 1MTPJ plantarflexion force during the forward
transfer of body weight in normal walking [46], we
speculate that reduced strength in this muscle group
may be related to the apropulsive gait patterns
previously observed in people with gout who demon-
strated reduced peak pressure beneath the hallux [26].
The authors proposed this was a pain-avoidance strat-
egy, which would reduce plantarflexor muscle activity
and may lead to disuse muscle atrophy.
Although participants with asymptomatic hyperuri-
caemia did not display the 1MTPJ-specific changes ob-
served in the gout group, they did report greater overall
foot pain and disability, reduced lower limb function
and increased activity limitation compared to the nor-
mouricaemic controls. It is unclear whether this is a dir-
ect result of chronically elevated serum urate and
subclinical MSU deposition, inflammation and tissue
damage [13–18] or related to co-existing conditions in-
cluding hypertension, obesity, cardiovascular disease
and diabetes, which have a marked association with
hyperuricaemia and may display clinical manifestations
in the foot and lower limb [48–54].
Table 4 Clinician-assessed outcomes
Parameter Mean
estimate
Diff. 95 % CI p
Lower Upper
ROM (°) Control (ref.) 77.6
Gout 59.7 −17.9 −26.8 −8.9 <0.001
Asymptomatic hyperuricaemia 76.8 −0.8 −9.3 7.7 0.853
Plantarflexion force (N) Control (ref.) 92.0
Gout 71.3 −20.7 −36.9 −4.6 0.012
Asymptomatic hyperuricaemia 114.8 22.8 7.5 38.1 0.004
Dorsiflexion force (N) Control (ref.) 57.3
Gout 58.0 0.8 −10.7 12.2 0.896
Asymptomatic hyperuricaemia 65.4 8.1 −2.7 19.0 0.139
Foot Posture Index Control (ref.) +4.8
Gout +6.2 1.3 −0.4 3.1 0.134
Asymptomatic hyperuricaemia +6.6 1.8 0.1 3.4 0.036
Plantar temperature (°C) Control (ref.) 24.3
Gout 26.2 1.9 0.6 3.1 0.004
Asymptomatic hyperuricaemia 25.1 0.8 −0.5 2.0 0.218
Dorsal temperature (°C) Control (ref.) 25.8
Gout 27.7 1.9 0.6 3.1 0.003
Asymptomatic hyperuricaemia 26.5 0.6 −0.6 1.9 0.295
Medial temperature (°C) Control (ref.) 25.2
Gout 27.0 1.8 0.6 3.1 0.004
Asymptomatic hyperuricaemia 25.9 0.8 −0.4 2.0 0.219
95 % CI for OR p
Lower Upper
Hallux Valgus Severitya Control (ref.)
Gout 0.284 0.085 0.947 0.041
Asymptomatic hyperuricaemia 0.968 0.968 0.296 0.957
aReference category: none (i.e. grade 0). The odds ratio represents the odds of the diagnostic group moving up one category of severity, compared to the control
group moving up one category of severity
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The association between chronically elevated serum
urate levels and patient-reported outcomes is unclear
and currently there is no consensus on the treatment of
asymptomatic hyperuricaemia due to the small number of
hyperuricaemic individuals that develop gout [10, 55] and
the side effects of treatment with urate lowering therapy
[56, 57]. However, the low-grade systemic inflammation,
which has been reported in patients with asymptomatic
hyperuricaemia [58, 59] along with the results of the
current study highlight the need for further research in
this area, particularly in the evaluation of treatment strat-
egies aimed at improving patient-reported outcomes.
Our findings should be considered in light of several
limitations. Firstly, our study included only male par-
ticipants so our results cannot be generalisable to both
genders. Secondly, we did not exclude participants
with diabetes, cardiovascular disease and hypertension,
which may have impacted our results. The majority of
patients with gout had advanced disease with tophi,
and it is possible that less severe 1MTPJ disease may
be present in those with early gout or without gouty
tophi. Lastly, the cross-sectional nature of our study
design limits the ability to determine the cause and
effect relationship between 1MTPJ characteristics and
different disease states.
Further research may employ methods of advanced
imaging to identify subclinical characteristics of gouty
arthritis at the 1MTPJ in people with gout and people
with asymptomatic hyperuricaemia in correlation to
clinically-assessed features of the joint. Considering
the lower-limb related functional impairments re-
ported by gout and asymptomatic hyperuricaemic par-
ticipants in the current study, future research may also
investigate how this is reflected in gait parameters. The
findings from this study may be useful in directing
future research, which evaluates the efficacy of non-
pharmacological treatment strategies, such as footwear
[60, 61] and orthoses, which specifically target the
1MTPJ in combination with urate lowering therapy.
Conclusion
In conclusion, this study has shown that 1MTPJ pain is
commonly reported by people with gout during inter-
critical periods. Clinician-assessed characteristics of
the joint, including reduced motion and increased
temperature, are indicative of subclinical inflammation
and highlight the impact of gout on the structure and
function of the 1MTPJ. This study has also shown that
people with asymptomatic hyperuricaemia, who do not
display any signs or symptoms of gout, also experience
considerable foot- and lower limb-related pain and im-
pairment and report greater activity limitation when
compared to normouricaemic controls.
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